Akero Therapeutics (AKRO)
(Real Time Quote from BATS)
$19.48 USD
-0.26 (-1.32%)
Updated Apr 29, 2024 03:56 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Income Statements
Fiscal Year end for Akero Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 173 | 115 | 101 | 80 | 46 |
Income After Depreciation & Amortization | -173 | -115 | -101 | -80 | -46 |
Non-Operating Income | 21 | 3 | 0 | 1 | 2 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -152 | -112 | -101 | -79 | -44 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -152 | -112 | -101 | -79 | -44 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -152 | -112 | -101 | -79 | -44 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -182 | -115 | -100 | -80 | -46 |
Depreciation & Amortization (Cash Flow) | -9 | 0 | 1 | 0 | 0 |
Income After Depreciation & Amortization | -173 | -115 | -101 | -80 | -46 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 52.57 | 38.99 | 34.83 | 31.46 | 15.07 |
Diluted EPS Before Non-Recurring Items | -2.89 | -2.87 | -2.89 | -2.52 | -2.90 |
Diluted Net EPS (GAAP) | -2.89 | -2.87 | -2.89 | -2.52 | -2.90 |
Fiscal Year end for Akero Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 61.87 | 46.61 | 35.63 | 28.76 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -61.87 | -46.61 | -35.63 | -28.76 |
Non-Operating Income | NA | 6.69 | 6.96 | 4.55 | 2.92 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -55.19 | -39.66 | -31.08 | -25.83 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -55.19 | -39.66 | -31.08 | -25.83 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -55.19 | -39.66 | -31.08 | -25.83 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 55.72 | 55.61 | 51.87 | 46.94 |
Diluted EPS Before Non-Recurring Items | NA | -0.99 | -0.71 | -0.60 | -0.55 |
Diluted Net EPS (GAAP) | NA | -1.03 | -0.71 | -0.60 | -0.55 |